Jyong Biotech’s CEO to Speak at 2025 Global Business Forum in Taipei

Posted on by

New Taipei City, Taiwan, Sept. 18, 2025 — Jyong Biotech Ltd. (Nasdaq: MENS), a Taiwan-based biotechnology firm focused on developing and marketing innovative plant-derived drugs, primarily for urinary system diseases, has announced that its Chairwoman and CEO, Fu Feng Kuo, will speak at the 2025 Global Business Forum in Taipei on September 19, 2025. The company’s initial target markets include the U.S., EU, and Asia.

Kuo will join other Taiwan biotech leaders to discuss aligning Taiwan’s biotech and medical industries with global trends. The Forum, a collaboration between the Taiwanese Chambers of Commerce of North America (TCCNA) and U.S. venture capital and biotech representatives, is designed to be a high-level international business platform.

The event aims to facilitate direct dialogue between key U.S. biotech decision-makers and leading Taiwanese drug development companies. Discussions will center on:

  • Innovative drug technology development
  • Cross-border clinical collaboration
  • Strategic capital deployment

About Jyong Biotech Ltd.

Jyong Biotech Ltd., headquartered in Taiwan, is a science-driven biotechnology company focused on developing and commercializing innovative plant-derived drugs, mainly for treating urinary system diseases. Its primary markets are the U.S., EU, and Asia. Since its founding in 2002, the company has developed integrated capabilities spanning all key aspects of drug development, including early-stage discovery, clinical trials, regulatory affairs, manufacturing, and commercialization. Jyong Biotech leverages strong R&D and a proprietary platform to develop botanical drug candidates, including its lead candidate, BOTRESO®, another clinical-stage candidate, and other preclinical candidates. The company aims to develop and provide innovative drugs to meet health needs and to be a well-regarded business.

For more information, please visit: , .

Forward-Looking Statement

This release includes forward-looking statements regarding plans, objectives, goals, strategies, future events, or performance, and underlying assumptions. The use of terms like “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions indicates forward-looking statements. These statements are not guarantees of future performance and involve risks and uncertainties that could cause actual results to differ materially from expectations. These risks and uncertainties include market conditions and other factors detailed in the “Risk Factors” section of the company’s SEC filings. Investors should not unduly rely on these forward-looking statements. Additional factors are discussed in the company’s SEC filings, available for review at . The company does not undertake to revise these statements to reflect events or circumstances after this date.

For more information, please contact:
Investor Relations
WFS Investor Relations Inc.
Janice Wang
Email:
Phone: +1 628 283 9214

“`